🇺🇸 FDA
Patent

US 11819554

Compositions and methods for modulating FMR1 expression

granted A61KA61K31/167A61K31/404

Quick answer

US patent 11819554 (Compositions and methods for modulating FMR1 expression) held by Fulcrum Therapeutics, Inc. expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fulcrum Therapeutics, Inc.
Grant date
Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/167, A61K31/404, A61K31/437, A61K31/4406